FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jonathan Cheng

Research Profile

Chemicals & Drugs

Disorders

Procedures

Living Beings

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jiping Zhang; Gregory P Adams; Hyung-Ok Lee; Wayne A Marasco; Stefanie R Mullins; Matthew K Robinson; Heidi Simmons; Matthildi Valianou; Louis M Weiner; Jonathan D Cheng
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Andre Konski; Tianyu Li; Alan Maurer; Neal J Meropol; Walter Scott; Jeffrey Tokar; Jian Q Yu; Jonathan D Cheng; Michael Christensen; Steven J Cohen; Kevin Crawford; Oleh Haluszka; Gary M Freedman
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jonathan Cheng (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jiping Zhang; Gregory P Adams; Hyung-Ok Lee; Wayne A Marasco; Stefanie R Mullins; Matthew K Robinson; Heidi Simmons; Matthildi Valianou; Louis M Weiner; Jonathan D Cheng
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2013;27(2):581-9.
2012: Andre Konski; Tianyu Li; Alan Maurer; Neal J Meropol; Walter Scott; Jeffrey Tokar; Jian Q Yu; Jonathan D Cheng; Michael Christensen; Steven J Cohen; Kevin Crawford; Oleh Haluszka; Gary M Freedman
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012;104(1):72-7.
2011: Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
American journal of clinical oncology 2011;34(1):70-5.
2011: Hyung-Ok Lee; Stefanie R Mullins; Matthildi Valianou; Edna Cukierman; Janusz Franco-Barraza; Jonathan D Cheng
FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.
BMC cancer 2011;11():245.
2010: Jiping Zhang; Matthildi Valianou; Jonathan D Cheng
Identification and characterization of the promoter of fibroblast activation protein.
Frontiers in bioscience (Elite edition) 2010;2():1154-63.
2008: Eric D Tetzlaff; Jonathan D Cheng; Jaffer A Ajani
Thromboembolism in gastrointestinal cancers.
Gastrointestinal cancer research : GCR 2008;2(6):267-72.
2008: Eric D Tetzlaff; Jonathan D Cheng; Jaffer A Ajani
Review of docetaxel in the treatment of gastric cancer.
Therapeutics and clinical risk management 2008;4(5):999-1007.
2008: Margaret von Mehren; Russell J Schilder; Jonathan D Cheng; E Temmer; T M Cardoso; F G Renshaw; E Bayever; Peter Zannikos; Z Yuan; Roger B Cohen
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1802-9.
2008: Steven J Cohen; R Katherine Alpaugh; Irma Palazzo; Neal J Meropol; André Rogatko; Zhiheng Xu; John P Hoffman; Louis M Weiner; Jonathan D Cheng
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Pancreas 2008;37(2):154-8.
2007: Kalyani Narra; Stefanie R Mullins; Hyung-Ok Lee; Brenda Strzemkowski-Brun; Kimberly Magalong; Victoria J Christiansen; Patrick A McKee; Brian Egleston; Steven J Cohen; Louis M Weiner; Neal J Meropol; Jonathan D Cheng
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.
Cancer biology & therapy 2007;6(11):1691-9.
2007: Andre Konski; Jonathan D Cheng; Melvyn Goldberg; Tianyu Li; Alan Maurer; Jian Q Yu; Oleh Haluszka; Walter Scott; Neal J Meropol; Steven J Cohen; Gary Freedman; Louis M Weiner
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
International journal of radiation oncology, biology, physics 2007;69(2):358-63.
2007: Leonard R Henry; Elin R Sigurdson; Eric A Ross; John S Lee; James C Watson; Jonathan D Cheng; Gary M Freedman; Andre Konski; John P Hoffman
Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome.
Annals of surgical oncology 2007;14(7):2000-9.
2007: Leonard R Henry; Hyung-Ok Lee; John S Lee; Andres Klein-Szanto; Perry Watts; Eric A Ross; Wen-Tien Chen; Jonathan D Cheng
Clinical implications of fibroblast activation protein in patients with colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1736-41.
2007: Leonard R Henry; Elin R Sigurdson; Eric A Ross; John S Lee; James C Watson; Jonathan D Cheng; Gary M Freedman; Andre Konski; John P Hoffman
Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome.
Annals of surgical oncology 2007;14(3):1081-91.
2006: Steven J Cohen; R Katherine Alpaugh; Steve Gross; S Mark O'Hara; Denis A Smirnov; Leon W M M Terstappen; W Jeffrey Allard; Maryann Bilbee; Jonathan D Cheng; John P Hoffman; Nancy L Lewis; Ann Pellegrino; André Rogatko; Elin R Sigurdson; Hao Wang; James C Watson; Louis M Weiner; Neal J Meropol
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.
Clinical colorectal cancer 2006;6(2):125-32.
2006: Leonard R Henry; Melvyn Goldberg; Walter Scott; Andre Konski; Neal J Meropol; Gary Freedman; Louis M Weiner; Perry Watts; Mary Beard; Susan McLaughlin; Jonathan D Cheng
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Annals of surgical oncology 2006;13(2):214-20.
2005: Andre Konski; John Hoffman; Elin R Sigurdson; Oleh Haluszka; Paul F Engstrom; Jonathan D Cheng; Steven J Cohen; James C Watson; Debra Eisenberg; Eileen McGarrity; Gary Freedman; Neal J Meropol
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience.
Seminars in oncology 2005;32(6 Suppl 9):S63-7.
2005: Adam C Berger; Walter J Scott; Gary Freedman; Andre Konski; Louis Weiner; Jonathan D Cheng; Melvyn Goldberg
Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer.
Seminars in oncology 2005;32(6 Suppl 9):S16-20.
2005: Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg
Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4330-7.
2005: Jonathan D Cheng; Matthildi Valianou; Adrian A Canutescu; Eileen K Jaffe; Hyung-Ok Lee; Hao Wang; Jack H Lai; William W Bachovchin; Louis M Weiner
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
Molecular cancer therapeutics 2005;4(3):351-60.
2004: Jonathan D Cheng; James S Babb; Corey Langer; Steinar Aamdal; Francisco Robert; Lars Rupert Engelhardt; Olov Fernberg; Joan Schiller; Goran Forsberg; R Katherine Alpaugh; Louis M Weiner; André Rogatko
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):602-9.
2003: Jonathan D Cheng; Louis M Weiner
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1590-5.
2002: Jonathan D Cheng; Roland L Dunbrack; Matthildi Valianou; André Rogatko; R Katherine Alpaugh; Louis M Weiner
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Cancer research 2002;62(16):4767-72.
1999: Jonathan D Cheng; B A Werness; James S Babb; Neal J Meropol
Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):1057-62.